These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Rational therapy for cutaneous T-cell lymphomas in the 1990s. Fact or fancy? Bunn PA Arch Dermatol; 1995 May; 131(5):603-5. PubMed ID: 7537952 [No Abstract] [Full Text] [Related]
5. Durable complete remission of therapy-refractory, tumor-stage cutaneous T-cell lymphoma under radioimmunotherapy with electron beam irradiation and denileukin diftitox. Wobser M; Göppner D; Lang SC; Beckmann G; Flentje M; Ugurel S; Bröcker EB; Becker JC Arch Dermatol; 2010 Jul; 146(7):805-6. PubMed ID: 20644054 [No Abstract] [Full Text] [Related]
6. Two novel therapies for the treatment of cutaneous T-cell lymphoma. LeMaistre CF Clin Lymphoma; 2000 Nov; 1 Suppl 1():S7. PubMed ID: 11707856 [No Abstract] [Full Text] [Related]
7. Advances in the treatment of non-Hodgkin lymphoma: interleukin-2 fusion toxin. A review of selected abstracts from the 2004 Annual Meeting of the American Society of Hematology. December 4-7, 2004, San Diego, California. Clin Adv Hematol Oncol; 2005 Mar; 3(3 Suppl 2):1-5; discussion 6-7. PubMed ID: 21434476 [No Abstract] [Full Text] [Related]
8. New advances in the management of cutaneous T-cell lymphoma. Young SK Cancer Pract; 2001; 9(1):52-4. PubMed ID: 11879274 [No Abstract] [Full Text] [Related]
9. Interleukin-2 fusion toxin: targeted therapy for cutaneous T cell lymphoma. Foss FM Ann N Y Acad Sci; 2001 Sep; 941():166-76. PubMed ID: 11594570 [TBL] [Abstract][Full Text] [Related]
11. Confirmation of the activity of the interleukin-2 fusion toxin denileukin diftitox against chemorefractory chronic lymphocytic leukemia, including cases with chromosome 17p deletions and without detectable CD25 expression. Morgan SJ; Seymour JF; Prince HM; Westerman DA; Wolf MM Clin Cancer Res; 2004 May; 10(10):3572-5. PubMed ID: 15161717 [No Abstract] [Full Text] [Related]
12. Cutaneous gamma/delta T-cell lymphoma treated with radiation and denileukin diftitox. Vidulich K; Jones D; Duvic M Clin Lymphoma Myeloma; 2008 Feb; 8(1):55-8. PubMed ID: 18501089 [TBL] [Abstract][Full Text] [Related]
13. Denileukin diftitox for the treatment of panniculitic lymphoma. McGinnis KS; Shapiro M; Junkins-Hopkins JM; Smith M; Lessin SR; Vittorio CC; Rook AH Arch Dermatol; 2002 Jun; 138(6):740-2. PubMed ID: 12056952 [No Abstract] [Full Text] [Related]
14. DAB(389)IL-2 (ONTAK): a novel fusion toxin therapy for lymphoma. Foss FM Clin Lymphoma; 2000 Sep; 1(2):110-6; discussion 117. PubMed ID: 11707818 [TBL] [Abstract][Full Text] [Related]